Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Corcept Therapeutics news
06.05.2022
Net income of Corcept Therapeutics under GAAP for the 3 months of 2022 was $22.797 million, down 2.8% from $23.465 million in the previous year. Revenue increased 17.9% to $93.688 million compared to $79.437 million a year earlier.
Source: 
ir.corcept.com
ir.corcept.com
16.02.2022
Corcept Therapeutics' GAAP net income for 2021 was $112.512 million, up 6.1% from $106.011 million in the prior year. Revenue increased 3.4% to $365.978 million from $353.874 million a year earlier.
Source: ir.corcept.com
ir.corcept.com
04.11.2021
Corcept Therapeutics reported a GAAP net profit of $80.459 million for 9M 2021, up 0.6% from $80.017 million in the previous year. Revenues decreased 0.4% to $267.156 million compared to $268.139 million a year earlier.
Source: ir.corcept.com
ir.corcept.com
30.07.2021
Corcept Therapeutics' GAAP net income for the six months of 2021 was $49.988 million, down 14.4% from $58.392 million in the previous year. Revenue decreased 5.9% to $171.025 million from $181.812 million a year earlier.
Source: ir.corcept.com
ir.corcept.com
General information
| Company name | Corcept Therapeutics |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 650.688.8803 |
| Mailing address | 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 |
| Website | www.corcept.com |
| Information disclosure | www.sec.gov |
English (US) 